{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:24:13Z","timestamp":1784557453959,"version":"3.55.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Despite the potential for its use as an agent of biowarfare or bioterrorism, no approved vaccine against staphylococcal enterotoxin B (SEB) exists. Nontoxic, mutant forms of SEB have been developed; however, it has been difficult to determine the efficacy of such subunit vaccine candidates due to the lack of superantigen activity of native SEB in rodents and due to the limitations of primate models. Since pigs respond to SEB in a manner similar to that of human subjects, we utilized this relevant animal model to investigate the safety and immunogenicity of a triple mutant of SEB carrying the amino acid changes L45R, Y89A, and Y94A. This recombinant mutant SEB (rmSEB) did not possess superantigen activity in pig lymphocyte cultures. Furthermore, rmSEB was unable to compete with native SEB for binding to pig leukocytes. These\n            <jats:italic>in vitro<\/jats:italic>\n            studies suggested that rmSEB could be a safe subunit vaccine. To test this possibility, piglets immunized orally with rmSEB formulations experienced no significant decrease in food consumption and no weight loss during the vaccination regimen. Oral vaccination with 1-mg doses of rmSEB on days 0, 7, 14, and 24 resulted in serum IgG and fecal IgA levels by day 36 that cross-reacted with native SEB. Surprisingly, the inclusion of cholera toxin adjuvant in vaccine formulations containing rmSEB did not result in increased antibody responses compared to formulations using the immunogen alone. Taken together, these studies provide additional evidence for the potential use of nontoxic forms of SEB as vaccines.\n          <\/jats:p>","DOI":"10.1128\/cvi.00078-10","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T01:56:49Z","timestamp":1276739809000},"page":"1163-1169","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Oral Vaccine Formulations Stimulate Mucosal and Systemic Antibody Responses against Staphylococcal Enterotoxin B in a Piglet Model"],"prefix":"10.1128","volume":"17","author":[{"given":"Tiffany K.","family":"Inskeep","sequence":"first","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Odle","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Oakes","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hudson","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Bost","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Piller","sequence":"additional","affiliation":[{"name":"Department of Animal Science, North Carolina State University, Raleigh, North Carolina 27695"},{"name":"Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina 28223"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1074\/jbc.M109369200","volume":"277","year":"2002","unstructured":"Baker, M. D., A. C. Papageorgiou, R. W. Titball, J. Miller, S. White, B. Lingard, J. J. Lee, D. Cavanagh, M. A. Kehoe, J. H. Robinson, and K. R. Acharya. 2002. Structural and functional role of threonine 112 in a superantigen Staphylococcus aureus enterotoxin B. J. Biol. Chem.277:2756-2762.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3181\/0901-RM-2","volume":"234","year":"2009","unstructured":"Bi, S., R. Das, E. Zelazowska, S. Mani, R. Neill, G. D. Coleman, D. C. Yang, R. Hammamieh, J. W. Shupp, and M. Jett. 2009. The cellular and molecular immune response of the weanling piglet to staphylococcal enterotoxin B. Exp. Biol. Med. (Maywood)234:1305-1315.","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1521-6616(03)00066-4","volume":"108","year":"2003","unstructured":"Boles, J. W., M. L. Pitt, R. D. LeClaire, P. H. Gibbs, E. Torres, B. Dyas, R. G. Ulrich, and S. Bavari. 2003. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin. Immunol.108:51-59.","journal-title":"Clin. Immunol."},{"key":"e_1_3_2_5_2","first-page":"412","volume":"278","year":"1997","unstructured":"Christopher, G. W., T. J. Cieslak, J. A. Pavlin, and E. M. Eitzen, Jr. 1997. Biological warfare. A historical perspective. JAMA278:412-417.","journal-title":"A historical perspective. JAMA"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/prep.2001.1556","volume":"24","year":"2002","unstructured":"Coffman, J. D., J. Zhu, J. M. Roach, S. Bavari, R. G. Ulrich, and S. L. Giardina. 2002. Production and purification of a recombinant staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli. Protein Expr. Purif.24:302-312.","journal-title":"Protein Expr. Purif."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/340828","volume":"185","year":"2002","unstructured":"DaSilva, L., B. C. Welcher, R. G. Ulrich, M. J. Aman, C. S. David, and S. Bavari. 2002. Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J. Infect. Dis.185:1754-1760.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.1.16"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00918083","volume":"12","year":"1992","unstructured":"Drake, C. G., and B. L. Kotzin. 1992. Superantigens: biology, immunology, and potential role in disease. J. Clin. Immunol.12:149-162.","journal-title":"J. Clin. Immunol."},{"key":"e_1_3_2_10_2","first-page":"29","volume":"146","year":"1989","unstructured":"Elson, C. O. 1989. Cholera toxin and its subunits as potential oral adjuvants. Curr. Top. Microbiol. Immunol.146:29-33.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0264-410X(98)00263-1","volume":"17","year":"1999","unstructured":"Foss, D. L., and M. P. Murtaugh. 1999. Mucosal immunogenicity and adjuvanticity of cholera toxin in swine. Vaccine17:788-801.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bios.2004.06.043","volume":"20","year":"2004","unstructured":"Hammamieh, R., S. Bi, R. Das, R. Neill, and M. Jett. 2004. Modeling of SEB-induced host gene expression to correlate in vitro to in vivo responses. Biosens. Bioelectron.20:719-727.","journal-title":"Biosens. Bioelectron."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.iy.09.040191.003525","volume":"9","year":"1991","unstructured":"Herman, A., J. W. Kappler, P. Marrack, and A. M. Pullen. 1991. Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol.9:745-772.","journal-title":"Annu. Rev. Immunol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1369-5274(98)80143-4","volume":"1","year":"1998","unstructured":"Kotb, M. 1998. Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr. Opin. Microbiol.1:56-65.","journal-title":"Curr. Opin. Microbiol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/17425247.3.6.747","volume":"3","year":"2006","unstructured":"Lavelle, E. C., and D. T. O'Hagan. 2006. Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug Deliv.3:747-762.","journal-title":"Expert Opin. Drug Deliv."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1074-7613(00)80646-9","volume":"9","year":"1998","unstructured":"Li, H., A. Llera, D. Tsuchiya, L. Leder, X. Ysern, P. M. Schlievert, K. Karjalainen, and R. A. Mariuzza. 1998. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity9:807-816.","journal-title":"Immunity"},{"key":"e_1_3_2_17_2","first-page":"57","volume":"96","year":"2006","unstructured":"Lutchman, D., S. Pillay, R. Naidoo, N. Shangase, R. Nayak, and A. Rughoobeer. 2006. Evaluation of the buffering capacity of powdered cow's, goat's and soy milk and non-prescription antacids in the treatment of non-ulcer dyspepsia. S. Afr. Med. J.96:57-61.","journal-title":"S. Afr. Med. J."},{"key":"e_1_3_2_18_2","first-page":"593","volume":"21","year":"2001","unstructured":"Madsen, J. M. 2001. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin. Lab Med.21:593-605.","journal-title":"A comparison and contrast with biological-warfare and chemical-warfare agents. Clin. Lab Med."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.2185544","volume":"248","year":"1990","unstructured":"Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science248:705-711.","journal-title":"Science"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0165-2427(97)00141-4","volume":"61","year":"1998","unstructured":"Mateu de Antonio, E., R. J. Husmann, R. Hansen, J. K. Lunney, D. Strom, S. Martin, and F. A. Zuckermann. 1998. Quantitative detection of porcine interferon-gamma in response to mitogen, superantigen and recall viral antigen. Vet. Immunol. Immunopathol.61:265-277.","journal-title":"Vet. Immunol. Immunopathol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3201\/eid0505.990502","volume":"5","year":"1999","unstructured":"Mead, P. S., L. Slutsker, V. Dietz, L. F. McCaig, J. S. Bresee, C. Shapiro, P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis.5:607-625.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","volume":"6","year":"2006","unstructured":"Neutra, M. R., and P. A. Kozlowski. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6:148-158.","journal-title":"Nat. Rev. Immunol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0966-842X(00)01793-5","volume":"8","year":"2000","unstructured":"Papageorgiou, A. C., and K. R. Acharya. 2000. Microbial superantigens: from structure to function. Trends Microbiol.8:369-375.","journal-title":"Trends Microbiol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0969-2126(97)00252-9","volume":"5","year":"1997","unstructured":"Papageorgiou, A. C., and K. R. Acharya. 1997. Superantigens as immunomodulators: recent structural insights. Structure5:991-996.","journal-title":"Structure"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/jmbi.1997.1577","volume":"277","year":"1998","unstructured":"Papageorgiou, A. C., H. S. Tranter, and K. R. Acharya. 1998. Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 \u00c5 resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J. Mol. Biol.277:61-79.","journal-title":"J. Mol. Biol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.3168\/jds.S0022-0302(91)78520-2","volume":"74","year":"1991","unstructured":"Park, Y. W. 1991. Relative buffering capacity of goat milk, cow milk, soy-based infant formulas and commercial nonprescription antacid drugs. J. Dairy Sci.74:3326-3333.","journal-title":"J. Dairy Sci."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3201\/eid1009.040250","volume":"10","year":"2004","unstructured":"Rusnak, J. M., M. Kortepeter, R. Ulrich, M. Poli, and E. Boudreau. 2004. Laboratory exposures to staphylococcal enterotoxin B. Emerg. Infect. Dis.10:1544-1549.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0167-7799(01)01670-5","volume":"19","year":"2001","unstructured":"Ryan, E. J., L. M. Daly, and K. H. Mills. 2001. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol.19:293-304.","journal-title":"Trends Biotechnol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/bsp.2006.0027","volume":"5","year":"2007","unstructured":"Salerno, R. M., and L. T. Hickok. 2007. Strengthening bioterrorism prevention: global biological materials management. Biosecur. Bioterror.5:107-116.","journal-title":"Biosecur. Bioterror."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.12.5333-5338.1993"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.4.2031-2036.2001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/359801a0","volume":"359","year":"1992","unstructured":"Swaminathan, S., W. Furey, J. Pletcher, and M. Sax. 1992. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature359:801-806.","journal-title":"Nature"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/nsb0895-680","volume":"2","year":"1995","unstructured":"Swaminathan, S., W. Furey, J. Pletcher, and M. Sax. 1995. Residues defining V beta specificity in staphylococcal enterotoxins. Nat. Struct. Biol.2:680-686.","journal-title":"Nat. Struct. Biol."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.8.2880-2885.1995"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0264-410X(98)00176-5","volume":"16","year":"1998","unstructured":"Ulrich, R. G., M. A. Olson, and S. Bavari. 1998. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine16:1857-1864.","journal-title":"Vaccine"},{"key":"e_1_3_2_36_2","first-page":"621","year":"1997","unstructured":"Ulrich, R. G., S. Sidell, and T. J. Taylor. 1997. Staphylococcal enterotoxin B and related pyogenic toxins, p. 621-631. In F. R. Sidell et al. (ed.), Textbook of military medicine. Part I. Warfare, weaponry and the casualty, vol. 3. U.S. Government Printing Office, Washington, DC.","journal-title":"Textbook of military medicine"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/153537020422901011","volume":"229","year":"2004","unstructured":"van Gessel, Y. A., S. Mani, S. Bi, R. Hammamieh, J. W. Shupp, R. Das, G. D. Coleman, and M. Jett. 2004. Functional piglet model for the clinical syndrome and postmortem findings induced by staphylococcal enterotoxin B. Exp. Biol. Med. (Maywood)229:1061-1071.","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vetimm.2004.08.012","volume":"103","year":"2005","unstructured":"Verdonck, F., V. Snoeck, B. M. Goddeeris, and E. Cox. 2005. Cholera toxin improves the F4(K88)-specific immune response following oral immunization of pigs with recombinant FaeG. Vet. Immunol. Immunopathol.103:21-29.","journal-title":"Vet. Immunol. Immunopathol."},{"key":"e_1_3_2_39_2","first-page":"31","year":"2005","unstructured":"World Health Organization. 2005. WHO guidelines on nonclinical evaluation of vaccines, p. 31-62. WHO Technical Report series no. 927. World Health Organization, Geneva, Switzerland.","journal-title":"WHO guidelines on nonclinical evaluation of vaccines,"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-3083.2001.00883.x","volume":"53","year":"2001","unstructured":"Yamamoto, M., J. R. McGhee, Y. Hagiwara, S. Otake, and H. Kiyono. 2001. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol.53:211-217.","journal-title":"Scand. J. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00078-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00078-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:43Z","timestamp":1627591423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00078-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1128\/CVI.00078-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00078-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"2010-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}